SEC Form 4 · accession 0001464583-26-000008
Kiniksa Pharmaceuticals International, plc · KNSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Megna
Officer — CHIEF ACCOUNTING OFFICER
Period of report
Jul 15, 2026
Accepted (ET)
Sep 3, 2026 · 4:40 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001730430
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Ordinary Share | Jul 15, 2026 | A | 279 | $33.50 | A | 27,697 | D | |
| Class A Ordinary ShareF2 | Sep 1, 2026 | M | 3,932 | — | A | 31,629 | D | |
| Class A Ordinary ShareF2 | Sep 1, 2026 | M | 2,558 | — | A | 34,187 | D | |
| Class A Ordinary ShareF2 | Sep 1, 2026 | M | 2,362 | — | A | 36,549 | D | |
| Class A Ordinary ShareF2 | Sep 1, 2026 | M | 2,644 | — | A | 39,193 | D | |
| Class A Ordinary Share | Sep 1, 2026 | F | 5,531 | $79.28 | D | 33,662 | D | |
| Class A Ordinary Share | Sep 3, 2026 | S | 4,600 | $80.30 | D | 29,062 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitF2,F4 | — | Sep 1, 2026 | A | 3,650 | A | — | — | Class A Ordinary Share | 3,650 | 3,650 | D |
| Share OptionF5 | $79.28 | Sep 1, 2026 | A | 14,600 | A | — | Aug 31, 2036 | Class A Ordinary Share | 14,600 | 14,600 | D |
| Restricted Share UnitF2,F6 | — | Sep 1, 2026 | M | 2,644 | D | — | — | Class A Ordinary Share | 2,644 | 7,931 | D |
| Restricted Share UnitF2,F7 | — | Sep 1, 2026 | M | 2,362 | D | — | — | Class A Ordinary Share | 2,362 | 4,725 | D |
| Restricted Share UnitF2,F8 | — | Sep 1, 2026 | M | 2,558 | D | — | — | Class A Ordinary Share | 2,558 | 2,557 | D |
| Restricted Share UnitF2,F9 | — | Sep 1, 2026 | M | 3,932 | D | — | — | Class A Ordinary Share | 3,932 | 0 | D |
Explanation of responses
- F1The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2026 to July 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e).
- F2Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
- F3This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025.
- F4The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.
- F5The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
- F6The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
- F7The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024.
- F8The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
- F9The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.